Predators and prey in the ocean rely on chemical signals for survival, but this vital sensory mode can also be their Achilles ...

Suven Life Sciences surged 9.51% to Rs 138.70 after the firm dosed first subjects in a Phase-1 clinical trial of SUVN-I6107 being conducted in USA under FDA acceptance of investigational new drug (IND ...

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery ...

We are excited to welcome Gil to the team,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. “His extensive expertise leading public company finance and capital ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully ...

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

After years of restructuring, Chicago-based Exicure has South Korean majority ownership and is buying the U.S. arm of a South ...

Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (“GPCR ...

(Nasdaq: XCUR, "Exicure", "the Company"), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. ("GPCR Therapeutics") on December 24, 2024, aimed at the ...

Researchers at the University of Chicago have revealed the complete structure of adhesion GPCRs, uncovering new activation mechanisms that could lead to more targeted drug treatments. Researchers at ...